International Stem Cell Corporation (OTCBB: ISCO) today announced
that it will hold a conference call and webcast on Wednesday, August 10,
2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich
will provide an update on the business, including plans for the future
development of the skin care line; animal and potential clinical trials
for Parkinson's and liver diseases; and the Company's business strategy
for 2011 and longer term.
Individuals interested in listening to the conference call may do so by
dialing 877-407-8033 for domestic callers, or 201-689-8033 for
international callers, or from the webcast on the investor relations
section of the Company's Web site at www.intlstemcell.com.
A telephone replay will be available approximately one hour after the
conclusion of the call by dialing 877-660-6853 for domestic callers, or
201-612-7415 for international callers, and entering the account code:
286 and the Conference ID: 376367. The webcast will be available on the
Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. ISCO's
core technology, parthenogenesis, results in the creation of pluripotent
human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing genders, ages and racial background. This offers the
potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for
therapeutic research worldwide through its subsidiary Lifeline Cell
Technology, and cell-based skin care products through its subsidiary
Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Lippert/Heilshorn
& Associates Don Markley, 310-691-7100 dmarkley@lhai.com |